– Aetna Inc, the third-largest U.S. health insurer, said it negotiated a
discount with Gilead Sciences Inc for its hepatitis C treatment and
will offer it as the preferred choice to nearly 11 million commercial
Aetna, which posted an updated
coverage policy on its website on Friday, said it believes the price it
received for Gilead’s Sovaldi, and a newer combination treatment called
Harvoni, is “competitive with other recently announced agreements for
this class of therapy.” It would not detail the size of the discount.